Mediwatch have now produced a 'Newsletter' which can be accessed from the link below or from their website.
Mediwatch Newsletter-December 2009
Thursday 24 December 2009
Monday 14 December 2009
Mediwatch-New Product Launch (updated 24th December)
The Mediwatch distributors are involved in a product launch for both the new Urodyn+ and Portaflow Advanced over this month (you have to be a distributor with a 'login' to follow the links further):
Updated 24th December 2009
"To view product launch video please select your prefered option from the below:
click to view high quality 56mb (Windows Media Video)
click to view medium quality 40mb (Windows Media Video)
click to view low quality 3mb (Windows Media Video)
click to view high quality 109mb (mp4)
click to view low quality 26mb (flash)
click to download high quality zip file
click to download low quality zip file"
Please select the day which your country appears.
December 14th
Algeria, Egypt, Greece, Iran, Iraq, Japan, Jordan, Kuwait, Lebanon, Libya, Oman, Palestine, Qatar, Saudi Arabia, Sudan, Syria, Tunisia, Turkey, United Arab Emirates and Yemen.
click to login
December 15th
Austria, Denmark, Finland, France, Germany, Israel, Norway, Poland, Russia and Switzerland.
December 16th
Argentina & Paraguay, India, Italy, Mexico, Peru, Philippines, Portugal, Spain and Venezuela.
December 17th
Hong Kong, Indonesia, Korea, Malaysia, Taiwan,Thailand.
New Product Launch
Updated 24th December 2009
"To view product launch video please select your prefered option from the below:
click to view high quality 56mb (Windows Media Video)
click to view medium quality 40mb (Windows Media Video)
click to view low quality 3mb (Windows Media Video)
click to view high quality 109mb (mp4)
click to view low quality 26mb (flash)
click to download high quality zip file
click to download low quality zip file"
Please select the day which your country appears.
December 14th
Algeria, Egypt, Greece, Iran, Iraq, Japan, Jordan, Kuwait, Lebanon, Libya, Oman, Palestine, Qatar, Saudi Arabia, Sudan, Syria, Tunisia, Turkey, United Arab Emirates and Yemen.
click to login
December 15th
Austria, Denmark, Finland, France, Germany, Israel, Norway, Poland, Russia and Switzerland.
December 16th
Argentina & Paraguay, India, Italy, Mexico, Peru, Philippines, Portugal, Spain and Venezuela.
December 17th
Hong Kong, Indonesia, Korea, Malaysia, Taiwan,Thailand.
New Product Launch
Wednesday 9 December 2009
What the ProtecT study has taught us to date
A view point on the UK ProtecT Study from the USA and 'The “New” Prostate Cancer InfoLink',of interest:
What the ProtecT study has taught us to date
Other Websites of interest:
ProtecT Study (Prostate testing for cancer and Treatment)
What the ProtecT study has taught us to date
Other Websites of interest:
ProtecT Study (Prostate testing for cancer and Treatment)
Boost For Prostate Cancer Screening - Report Shows Mortality Reduction As High As 31%
Article Date: 09 Dec 2009
The effectiveness of PSA (prostate-specific antigen) screening on reducing prostate cancer mortality has been given a boost with new data from the European Randomized Study of Screening for Prostate Cancer (ERSPC). This shows the true impact to be far higher than previously reported up to 31%.
Preliminary ERSPC findings showed that screening reduced prostate cancer deaths by 20%. This latest ERSPC analysis corrects for non-attendance and contamination to assess the effectiveness of PSA testing in those men actually screened
From 1992, the ERSPC study randomized 162,000 men, aged 55 to 69, in seven European countries to either a screening arm or a control group. Those screened were given a blood test to detect PSA levels: if it was 3.0ng/ml or more, they were offered a biopsy. Screening took place on average every four years. Mean follow-up was nine years.
In any randomized trial, some in the screening arm do not attend and some in the control group inadvertently receive a PSA test (contamination). Contamination makes it difficult to detect differences. This is believed to be one reason why the Prostate Lung, Colon and Ovarian (PLCO) study failed to detect any significant reduction in mortality.
PSA cut off level of 3ng/ml is safer threshold for reducing biopsies
Using retrospective data from the Dutch arm, the ERSPC has shown that using a screening algorithm - an individual risk assessment - alongside PSA testing can reduce the number of unnecessary biopsies. PSA testing is sensitive but not specific, so elevated levels do not necessarily imply cancer. Approximately 30% of detected cancers are non-aggressive - 'indolent' or slow growing.
Their findings, published in January 2010's European Urology suggest that a PSA cut off level of 3ng/ml combined with an individual risk assessment would reduce biopsies by 33%. The majority of cancers potentially missed would be indolent, so there would be no benefit from active treatment. Increasing the PSA cut-off level from 3 to 4 ng/ml may save a similar number of biopsies, but will miss more clinically significant cancers.
Source: European Randomized Study of Screening for Prostate Cancer
Boost For Prostate Cancer Screening - Report Shows Mortality Reduction As High As 31%
The effectiveness of PSA (prostate-specific antigen) screening on reducing prostate cancer mortality has been given a boost with new data from the European Randomized Study of Screening for Prostate Cancer (ERSPC). This shows the true impact to be far higher than previously reported up to 31%.
Preliminary ERSPC findings showed that screening reduced prostate cancer deaths by 20%. This latest ERSPC analysis corrects for non-attendance and contamination to assess the effectiveness of PSA testing in those men actually screened
From 1992, the ERSPC study randomized 162,000 men, aged 55 to 69, in seven European countries to either a screening arm or a control group. Those screened were given a blood test to detect PSA levels: if it was 3.0ng/ml or more, they were offered a biopsy. Screening took place on average every four years. Mean follow-up was nine years.
In any randomized trial, some in the screening arm do not attend and some in the control group inadvertently receive a PSA test (contamination). Contamination makes it difficult to detect differences. This is believed to be one reason why the Prostate Lung, Colon and Ovarian (PLCO) study failed to detect any significant reduction in mortality.
PSA cut off level of 3ng/ml is safer threshold for reducing biopsies
Using retrospective data from the Dutch arm, the ERSPC has shown that using a screening algorithm - an individual risk assessment - alongside PSA testing can reduce the number of unnecessary biopsies. PSA testing is sensitive but not specific, so elevated levels do not necessarily imply cancer. Approximately 30% of detected cancers are non-aggressive - 'indolent' or slow growing.
Their findings, published in January 2010's European Urology suggest that a PSA cut off level of 3ng/ml combined with an individual risk assessment would reduce biopsies by 33%. The majority of cancers potentially missed would be indolent, so there would be no benefit from active treatment. Increasing the PSA cut-off level from 3 to 4 ng/ml may save a similar number of biopsies, but will miss more clinically significant cancers.
Source: European Randomized Study of Screening for Prostate Cancer
Boost For Prostate Cancer Screening - Report Shows Mortality Reduction As High As 31%
Tuesday 8 December 2009
NEWS-Week Ending 13th December(Updated-5 Posts)
Beer may cut prostate cancer risk 9th December
Prostate test backed by study Europe-8th December
Coffee could help cut prostate cancer risk USA-8th December
Exercise can reduce overall mortality rates in patients with prostate cancer,according to findings USA-8th December
New National Report Shows Cancer Rates Continue To Decline USA-8th December
Prostate test backed by study Europe-8th December
Coffee could help cut prostate cancer risk USA-8th December
Exercise can reduce overall mortality rates in patients with prostate cancer,according to findings USA-8th December
New National Report Shows Cancer Rates Continue To Decline USA-8th December
Wednesday 2 December 2009
Tuesday 1 December 2009
NEWS-Week Ending 6th December(Updated-2 Posts)
BBC-Prostate Cancer Information UK-1st December (Highlighted on website today)
NHS 'must get better at early cancer diagnosis' UK-1st December
NHS 'must get better at early cancer diagnosis' UK-1st December
Subscribe to:
Posts (Atom)